1887

Chapter 12 : Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap12-1.gif /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap12-2.gif

Abstract:

This chapter reviews agents which have been, or are being, developed to treat herpesvirus, hepatitis virus, and respiratory virus infections. Detailed information is provided for approved agents and those in more advanced stages of clinical development. Agents in phase I human studies or promising approaches which are still in preclinical development are described briefly. The anti-herpes simplex virus (HSV) activity of acyclovir demonstrated that analogs of guanosine were active and that acyclic side chains could substitute for the ribose moiety, conferring specificity by the selective uptake and activation of acyclovir in HSV-infected cells. Thymidine kinase-deficient or -altered HSV or varicella-zoster virus (VZV) isolates resistant to acyclovir remain susceptible in vitro to foscarnet, cidofovir, and brivudine but are fully cross-resistant to ganciclovir and famciclovir. The more convenient dosing schedule of famciclovir and the potentially shorter duration of postherpetic neuralgia argue in favor of employing famciclovir or valacyclovir for herpes zoster, particularly in older individuals, in whom the complication of postherpetic neuralgia is more frequent. Cidofovir has been primarily developed as an anti-CMV agent but has broad antiherpesvirus activity. New antiherpesvirus drugs include inhibitors of immediate early gene expression, nonnucleoside DNA polymerase inhibitors, helicase-primase inhibitors, inhibitors of protein-protein interactions among DNA replication proteins, and inhibitors of assembly, encapsidation, and nuclear egress. The chapter describes agents that are primarily or exclusively directed at treatment of hepatitis virus infection. Antiviral activities of ribavirin are also described.

Citation: Yin M, Brust J, Tieu H, Hammer S. 2009. Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents, p 217-264. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch12

Key Concept Ranking

Viral Diseases
0.89991474
Infection and Immunity
0.8782079
Neuraminidase Inhibitors
0.8461837
Assembly Inhibitors
0.8394049
Protease Inhibitors
0.8378107
0.89991474
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Chemical structures of antiherpesvirus agents.

Citation: Yin M, Brust J, Tieu H, Hammer S. 2009. Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents, p 217-264. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Chemical structures of anti-HCV agents.

Citation: Yin M, Brust J, Tieu H, Hammer S. 2009. Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents, p 217-264. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Inhibition of HCV replication cycle by antiviral agents. After surface-bound HCV is internalized via receptor-mediated endocytosis, fusion of the viral envelope and cellular endosomal membrane occurs and the HCV RNA is passaged to the endoplasmic reticulum (ER). The internal ribosome entry site (IRES) directs the binding of the viral RNA to cytoplasmic ribosomal subunits and initiates translation. The large polyprotein precursor is processed by cellular and viral proteases into structural and nonstructural proteins. The viral NS3/NS4A protease is the target of HCV protease inhibitors. The viral NS5B enzyme, RNA polymerase, is responsible for the initial synthesis of a complementary negative-strand RNA template and the subsequent synthesis of positive-strand RNA [(+)RNA] and is the target of the HCV polymerase inhibitors. The final step of HCV replication consists of viral assembly and release. α-Glucosidase I is a host enzyme that is essential for the proper glycosylation of viral envelope proteins, and is the target of α-glucosidase inhibitors. MW, membranous web. (Adapted from reference with permission [http://clinicaloptions.com/hiventry].)

Citation: Yin M, Brust J, Tieu H, Hammer S. 2009. Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents, p 217-264. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Chemical structures of anti-HBV agents.

Citation: Yin M, Brust J, Tieu H, Hammer S. 2009. Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents, p 217-264. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

Chemical structures of amantadine (left) and rimantadine (right).

Citation: Yin M, Brust J, Tieu H, Hammer S. 2009. Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents, p 217-264. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 6
FIGURE 6

Chemical structures of anti-influenza virus agents.

Citation: Yin M, Brust J, Tieu H, Hammer S. 2009. Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents, p 217-264. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815981.ch12
1. Abed, Y.,, and G. Boivin. 2006. Treatment of respiratory virus infections. Antivir. Res. 70:116.
2. Andrei, G.,, J. Balzarini,, P. Fiten,, E. De Clercq,, G. Opdenakker, and, R. Snoeck. 2005. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin. J. Virol. 79:58635869.
3. Andrei, G.,, E. De Clercq, and, R. Snoeck. 2004. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antivir. Res. 61:181187.
4. Anonymous. 1992. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N. Engl. J. Med. 326:213220.
5. Anonymous. 2002. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133:467474.
6. Anonymous. 2002. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am. J. Ophthalmol. 133:475483.
7. Aoki, F. Y.,, and D. S. Sitar. 1988. Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet. 14:3551.
8. Aoki, F. Y.,, S. Tyring,, F. Diaz-Mitoma,, G. Gross,, J. Gao, and, K. Hamed. 2006. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 42:813.
9. Ashley, R. L.,, and L. Corey. 1984. Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. J. Clin. Investig. 73:681688.
10. Aweeka, F.,, J. Gambertoglio,, J. Mills, and, M. A. Jacobson. 1989. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob. Agents Chemother. 33:742745.
11. Aweeka, F. T.,, J. G. Gambertoglio,, F. Kramer,, C. van der Horst,, B. Polsky,, A. Jayewardene,, P. Lizak,, L. Emrick,, W. Tong, and, M. A. Jacobson. 1995. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. Clin. Pharmacol. Ther. 57:403412.
12. Aweeka, F. T.,, J. G. Gambertoglio,, C. van der Horst,, R. Raasch, and, M. A. Jacobson. 1992. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrob. Agents Chemother. 36:17731778.
13. Aweeka, F. T.,, M. Kang,, J. Y. Yu,, P. Lizak,, B. Alston, and, R. T. Chung. 2007. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med. 8:288294.
14. Bain, V. G.,, K. D. Kaita,, E. M. Yoshida,, M. G. Swain,, E. J. Heathcote,, A. U. Neumann,, M. Fiscella,, R. Yu,, B. L. Osborn,, P. W. Cronin,, W. W. Freimuth,, J. G. McHutchison, and, G. M. Subramanian. 2006. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol. 44:671678.
15. Balfour, H. H.,, Jr., C. Benson,, J. Braun,, B. Cassens,, A. Erice,, A. Friedman-Kien,, T. Klein,, B. Polsky, and, S. Safrin. 1994. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J. Acquir. Immune Defic. Syndr. 7:254260.
16. Bantia, S.,, C. S. Arnold,, C. D. Parker,, R. Upshaw, and, P. Chand. 2006. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antivir. Res. 69:3945.
17. Reference deleted.
18. Bell, W. R.,, J. D. Chulay, and, J. E. Feinberg. 1997. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 76:369380.
19. Belshe, R. B.,, M. H. Smith,, C. B. Hall,, R. Betts, and, A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:15081512.
20. Bernstein, D. I.,, S. L. Spruance,, S. S. Arora,, J. L. Schroeder, and, T. C. Meng. 2005. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin. Infect. Dis. 41:808814.
21. Bifano, M.,, J. H. Yan,, R. A. Smith,, D. Zhang,, D. M. Grasela, and, F. Lacreta. 2007. Absence of a pharmacokinetic interaction between entecavir and adefovir. J. Clin. Pharmacol. 47:13271334.
22. Biron, K. K.,, R. J. Harvey,, S. C. Chamberlain,, S. S. Good,, A. A. Smith III,, M. G. Davis,, C. L. Talarico,, W. H. Miller,, R. Ferris,, R. E. Dornsife,, S. C. Stanat,, J. C. Drach,, L. B. Townsend, and, G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:23651272.
23. Bode, L.,, D. E. Dietrich,, R. Stoyloff,, H. M. Emrich, and, H. Ludwig. 1997. Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 349:178179.
24. Boivin, G.,, M. Baz, and, Y. Abed. 2007. Abstr. F1-946. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
25. Boivin, G.,, and N. Goyette. 2002. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antivir. Res. 54:143147.
26. Boivin, G.,, N. Goyette,, C. Gilbert, and, E. Covington. 2005. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J. Med. Virol. 77:425429.
27. Bonfanti, J. F.,, C. Meyer,, F. Doublet,, J. Fortin,, P. Muller,, L. Queguiner,, T. Gevers,, P. Janssens,, H. Szel,, R. Willebrords,, P. Timmerman,, K. Wuyts,, P. van Remoortere,, F. Janssens,, P. Wigerinck, and, K. Andries. 2008. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J. Med. Chem. 51:875896. [Epub ahead of print.]
28. Boon, R.,, J. J. Goodman,, J. Martinez,, G. L. Marks,, M. Gamble, and, C. Welch for the Penciclovir Cream Herpes Labialis Study Group. 2000. Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Clin. Ther. 22:7690.
29. Boon, R. J.,, and D. R. Griffin. 1995. Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Neurology 45:S76S77.
30. Bray, M.,, M. Martinez,, D. Kefauver,, M. West, and, C. Roy. 2002. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antivir. Res. 54:129142.
31. Brinkman, K.,, J. A. Smeitink,, J. A. Romijn, and, P. Reiss. 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:11121115.
32. Butt, A. A. 2003. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read. 13:344348.
33. Carmack, M. A.,, and C. G. Prober. 1995. Respiratory syncytial virus: antiviral therapy, p. 357–390. In D. J. Jeffries and, E. DeClerq (ed.), Antiviral Chemotherapy. John Wiley & Sons, Ltd., Chichester, United Kingdom.
34. Cass, L. M.,, K. A. Gunawardena,, M. M. Macmahon, and, A. Bye. 2000. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir. Med. 94:166173.
35. Centers for Disease Control and Prevention. 2008. Update: influenza activity—United States, September 30, 2007–February 9, 2008. Morb. Mortal. Wkly. Rep. 57:15.
36. Chan, H. L.,, E. J. Heathcote,, P. Marcellin,, C. L. Lai,, M. Cho,, Y. M. Moon,, Y. C. Chao,, R. P. Myers,, G. Y. Minuk,, L. Jeffers,, W. Sievert,, N. Bzowej,, G. Harb,, R. Kaiser,, X. J. Qiao, and, N. A. Brown. 2007. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med. 147:745754.
37. Chang, T. T.,, R. G. Gish,, R. de Man,, A. Gadano,, J. Sollano,, Y. C. Chao,, A. S. Lok,, K. H. Han,, Z. Goodman,, J. Zhu,, A. Cross,, D. DeHertogh,, R. Wilber,, R. Colonno, and, D. Apelian. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354:10011010.
38. Chang, T. T.,, and C. L. Lai. 2006. Hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. 355:322323. (Author’s reply, 355: 323.)
39. Cherrington, J. M.,, M. D. Fuller,, P. D. Lamy,, R. Miner,, J. P. Lalezari,, S. Nuessle, and, W. L. Drew. 1998. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. J. Infect. Dis. 178:18211825.
40. Cherrington, J. M.,, A. S. Mulato,, M. D. Fuller, and, M. S. Chen. 1996. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy) ethyl]adenine in vitro. Antimicrob. Agents Chemother. 40:22122216.
41. Chosidow, O.,, Y. Drouault,, F. Leconte-Veyriac,, M. Aymard,, J. P. Ortonne,, F. Pouget,, J. Revuz,, J. M. Decazes, and, J. E. Malkin. 2001. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br. J. Dermatol. 144:818824.
42. Chou, S.,, and G. I. Marousek. 2006. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob. Agents Chemother. 50:34703472.
43. Chou, S.,, L. C. Wechel, and, G. I. Marousek. 2007. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 196:9194.
44. Clark, J. L.,, L. Hollecker,, J. C. Mason,, L. J. Stuyver,, P. M. Tharnish,, S. Lostia,, T. R. McBrayer,, R. F. Schinazi,, K. A. Watanabe,, M. J. Otto,, P. A. Furman,, W. J. Stec,, S. E. Patterson, and, K. W. Pankiewicz. 2005. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 48:55045508.
45. Reference deleted.
46. Coen, D. M. 1991. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antivir. Res. 15:287300.
47. Coen, D. M.,, and P. A. Schaffer. 2003. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Discov. 2:278288.
48. Corey, L.,, A. J. Nahmias,, M. E. Guinan,, J. K. Benedetti,, C. W. Critchlow, and, K. K. Holmes. 1982. A trial of topical acyclovir in genital herpes simplex virus infections. N. Engl. J. Med. 306:13131319.
49. Cundy, K. C.,, B. G. Petty,, J. Flaherty,, P. E. Fisher,, M. A. Polis,, M. Wachsman,, P. S. Lietman,, J. P. Lalezari,, M. J. Hitchcock, and, H. S. Jaffe. 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39:12471252.
50. Curran, M.,, and S. Noble. 2001. Valganciclovir. Drugs 61:11451150; discussion, 1151–1152.
51. Dal Pero, F.,, K. H. Tang,, M. Gerotto,, G. Bortoletto,, E. Paulon,, E. Herrmann,, S. Zeuzem,, A. Alberti, and, N. V. Naoumov. 2007. Impact of NS5A sequences of hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J. Infect. Dis. 196:9981005.
52. Darnell, J. E.,, Jr., I. M. Kerr, and, G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:14151421.
53. Das, K.,, X. Xiong,, H. Yang,, C. E. Westland,, C. S. Gibbs,, S. G. Sarafianos, and, E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75:47714779.
54. Davis, J. L.,, I. Taskintuna,, W. R. Freeman,, D. V. Weinberg,, W. J. Feuer, and, R. E. Leonard. 1997. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch. Ophthalmol. 115:733737.
55. De Clercq, E. 2004. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem. Pharmacol. 68:23012315.
56. De Clercq, E. 1986. Towards a selective chemotherapy of virus infections. Development of bromovinyldeoxyuridine as a highly potent and selective antiherpetic drug. Verh. K. Acad. Geneeskd. Belg. 48:261290.
57. de Jong, M. D.,, T. T. Tran,, H. K. Truong,, M. H. Vo,, G. J. Smith,, V. C. Nguyen,, V. C. Bach,, T. Q. Phan,, Q. H. Do,, Y. Guan,, J. S. Peiris,, T. H. Tran, and, J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:26672672.
58. Del Poggio, P.,, M. Zaccanelli,, M. Oggionni,, S. Colombo,, C. Jamoletti, and, V. Puhalo. 2007. Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. World J. Gastroenterol. 13:40964099.
59. DeVincenzo, J.,, J. E. Cehelsky,, R. Alvarez,, S. Elbashir,, J. Harborth,, I. Toudjarska,, L. Nechev,, V. Murugaiah,, A. Van Vliet,, A. K. Vaishnaw, and, R. Meyers. 2008. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antivir. Res. 77:225231.
60. Deyde, V. M.,, X. Xu,, R. A. Bright,, M. Shaw,, C. B. Smith,, Y. Zhang,, Y. Shu,, L. V. Gubareva,, N. J. Cox, and, A. I. Klimov. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196:249257.
61. Douglas, R. G., Jr. 1990. Prophylaxis and treatment of influenza. N. Engl. J. Med. 322:443450.
62. Drew, W. L. 1992. Cytomegalovirus infection in patients with AIDS. Clin. Infect. Dis. 14:608615.
63. Drew, W. L.,, R. C. Miner,, D. F. Busch,, S. E. Follansbee,, J. Gullett,, S. G. Mehalko,, S. M. Gordon,, W. F. Owen, Jr.,, T. R. Matthews,, W. C. Buhles, et al. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716719.
64. Drew, W. L.,, R. C. Miner,, G. I. Marousek, and, S. Chou. 2006. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 37:124127.
65. Earnshaw, D. L.,, T. H. Bacon,, S. J. Darlison,, K. Edmonds,, R. M. Perkins, and, R. A. Vere Hodge. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36:27472757.
66. Eid, A. J.,, S. K. Arthurs,, P. J. Deziel,, M. P. Wilhelm, and, R. R. Razonable. 2008. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin. Transplant. 22:162170.
67. Eisenberg, E. J.,, A. Bidgood, and, K. C. Cundy. 1997. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob. Agents Chemother. 41:19491952.
68. Elion, G. B. 1982. Mechanism of action and selectivity of acyclovir. Am. J. Med. 73:713.
69. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286297.
70. Fardeau, C.,, M. Langlois,, B. Mathys,, P. Rafales,, F. Nugier,, V. Godard,, M. Aymard, and, J. Denis. 1991. Emergence of cross-resistant herpes simplex virus following topical drug therapy in rabbit keratitis. Curr. Eye Res. 10(Suppl.):151158.
71. Farrar, M. A.,, and R. D. Schreiber. 1993. The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11:571611.
72. Feldstein, T. J.,, J. L. Swegarden,, G. F. Atwood, and, C. D. Peterson. 1995. Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy. Pediatrics 96:1417.
73. Field, A. K.,, M. E. Davies,, C. DeWitt,, H. C. Perry,, R. Liou,, J. Germershausen,, J. D. Karkas,, W. T. Ashton,, D. B. Johnston, and, R. L. Tolman. 1983. 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA 80:41394143.
74. Fife, K. H.,, R. A. Barbarash,, T. Rudolph,, B. Degregorio, and, R. Roth for The Valaciclovir International Herpes Simplex Virus Study Group. 1997. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. Sex. Transm. Dis. 24:481486.
75. Filer, C. W.,, G. D. Allen,, T. A. Brown,, S. E. Fowles,, F. J. Hollis,, E. E. Mort,, W. T. Prince, and, J. V. Ramji. 1994. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica 24:357368.
76. Fletcher, C. V.,, E. P. Acosta,, H. Cheng,, R. Haubrich,, M. Fischl,, R. Raasch,, C. Mills,, X. J. Hu,, D. Katzenstein,, R. P. Remmel, and, R. M. Gulick. 2000. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS 14:24952501.
77. Flisiak, R. H.,, A. Horbans,, P. Gallay,, M. Bobardt,, S. Selvarajah,, A. Wiercinska-Drapalo,, E. Siwak,, I. Cielniak,, J. Kierkus,, J. Higersberger,, C. Aeschlimann,, P. Grosgurin,, V. Nicolas-Métral,, J.-M. Dumont,, H. Porchet,, R. Crabbé, and, P. Scalfaro. 2008. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis and human immunodeficiency virus. Hepatology 47:817826.
78. Fong, T. L.,, M. W. Fried, and, J. Clarke-Platt. 1999. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy. Am. J. Gastroenterol. 94:990993.
79. Fried, M. W.,, M. L. Shiffman,, K. R. Reddy,, C. Smith,, G. Marinos,, F. L. Goncales, Jr.,, D. Haussinger,, M. Diago,, G. Carosi,, D. Dhumeaux,, A. Craxi,, A. Lin,, J. Hoffman, and, J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975982.
80. Funch, D. P.,, A. M. Walker,, G. Schneider,, N. J. Ziyadeh, and, M. D. Pescovitz. 2005. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am. J. Transplant. 5:28942900.
81. Fung, S. K.,, P. Andreone,, S. H. Han,, K. Rajender Reddy,, A. Regev,, E. B. Keeffe,, M. Hussain,, C. Cursaro,, P. Richtmyer,, J. A. Marrero, and, A. S. Lok. 2005. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 43:937943.
82. Fyfe, J. A. 1982. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol. Pharmacol. 21:432437.
83. Gilbert, C.,, J. Bestman-Smith, and, G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updates 5:88114.
84. Gish, R. G. 2006. Treating HCV with ribavirin analogues and ribavirin-like molecules. J. Antimicrob. Chemother. 57:813.
85. Gish, R. G.,, S. Arora,, K. Rajender Reddy,, D. R. Nelson,, C. O’Brien,, Y. Xu, and, B. Murphy. 2007. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J. Hepatol. 47:5159.
86. Griffiths, P. D.,, J. E. Feinberg,, J. Fry,, C. Sabin,, L. Dix,, D. Gor,, A. Ansari, and, V. C. Emery for the AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. 1998. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. J. Infect. Dis. 177:5764.
87. Gubareva, L. V.,, M. N. Matrosovich,, M. K. Brenner,, R. C. Bethell, and, R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:12571262.
88. Gubareva, L. V.,, R. G. Webster, and, F. G. Hayden. 2001. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 45:34033408.
89. Hadziyannis, S. J. 2006. New developments in the treatment of chronic hepatitis B. Expert Opin. Biol. Ther. 6:913921.
90. Hadziyannis, S. J.,, H. Sette, Jr.,, T. R. Morgan,, V. Balan,, M. Diago,, P. Marcellin,, G. Ramadori,, H. Bodenheimer, Jr.,, D. Bernstein,, M. Rizzetto,, S. Zeuzem,, P. J. Pockros,, A. Lin, and, A. M. Ackrill. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346355.
91. Hadziyannis, S. J.,, N. C. Tassopoulos,, E. J. Heathcote,, T. T. Chang,, G. Kitis,, M. Rizzetto,, P. Marcellin,, S. G. Lim,, Z. Goodman,, J. Ma,, S. Arterburn,, S. Xiong,, G. Currie, and, C. L. Brosgart. 2005. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 352:26732681.
92. Hadziyannis, S. J.,, N. C. Tassopoulos,, E. J. Heathcote,, T. T. Chang,, G. Kitis,, M. Rizzetto,, P. Marcellin,, S. G. Lim,, Z. Goodman,, M. S. Wulfsohn,, S. Xiong,, J. Fry, and, C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800807.
93. Hardy, D.,, S. Spector,, B. Polsky,, C. Crumpacker,, C. van der Horst,, G. Holland,, W. Freeman,, M. H. Heinemann,, G. Sharuk,, J. Klystra, et al. 1994. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. Eur. J. Clin. Microbiol. Infect. Dis. 13(Suppl. 2):S34S40.
94. Hatakeyama, S.,, N. Sugaya,, M. Ito,, M. Yamazaki,, M. Ichikawa,, K. Kimura,, M. Kiso,, H. Shimizu,, C. Kawakami,, K. Koike,, K. Mitamura, and, Y. Kawaoka. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:14351442.
95. Hatziioannou, T.,, D. Perez-Caballero,, S. Cowan, and, P. D. Bieniasz. 2005. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J. Virol. 79:176183.
96. Hayden, F. G.,, R. L. Atmar,, M. Schilling,, C. Johnson,, D. Poretz,, D. Paar,, L. Huson,, P. Ward, and, R. G. Mills. 1999. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 341:13361343.
97. Hayden, F. G.,, L. V. Gubareva,, A. S. Monto,, T. C. Klein,, M. J. Elliot,, J. M. Hammond,, S. J. Sharp, and, M. J. Ossi for The Zanamivir Family Study Group. 2000. Inhaled zanamivir for the prevention of influenza in families. N. Engl. J. Med. 343:12821289.
98. Hayden, F. G.,, and A. T. Pavia. 2006. Antiviral management of seasonal and pandemic influenza. J. Infect. Dis. 194(Suppl. 2):S119S126.
99. Hazari, S.,, L. Taylor,, S. Haque,, R. F. Garry,, S. Florman,, R. Luftig,, F. Regenstein, and, S. Dash. 2007. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol. J. 4:89.
100. He, G.,, J. Massarella, and, P. Ward. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471484.
101. Hengge, U. R.,, N. H. Brockmeyer,, R. Malessa,, U. Ravens, and, M. Goos. 1993. Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob. Agents Chemother. 37:10101014.
102. Ho, H. T.,, K. L. Woods,, J. J. Bronson,, H. De Boeck,, J. C. Martin, and, M. J. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 41:197202.
103. Holland, G. N.,, R. D. Levinson, and, M. A. Jacobson for the AIDS Clinical Trials Group Protocol 915 Team. 1995. Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. Am. J. Ophthalmol. 119:576586.
104. Ilyushina, N. A.,, N. V. Bovin,, R. G. Webster, and, E. A. Govorkova. 2006. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antivir. Res. 70:121131.
105. Innaimo, S. F.,, M. Seifer,, G. S. Bisacchi,, D. N. Standring,, R. Zahler, and, R. J. Colonno. 1997. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41:14441448.
106. Inoue, K.,, K. Sekiyama,, M. Yamada,, T. Watanabe,, H. Yasuda, and, M. Yoshiba. 2003. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. 38:567572.
107. Inoue, K.,, T. Umehara,, U. T. Ruegg,, F. Yasui,, T. Watanabe,, H. Yasuda,, J. M. Dumont,, P. Scalfaro,, M. Yoshiba, and, M. Kohara. 2007. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45:921928.
108. Ison, M. G.,, J. W. Gnann, Jr.,, S. Nagy-Agren,, J. Treannor,, C. Paya,, R. Steigbigel,, M. Elliott,, H. L. Weiss, and, F. G. Hayden. 2003. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 8:183190.
109. Ison, M. G.,, L. V. Gubareva,, R. L. Atmar,, J. Treanor, and, F. G. Hayden. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760764.
110. Jabs, D. A.,, C. Enger,, M. Forman, and, J. P. Dunn for The Cytomegalovirus Retinitis and Viral Resistance Study Group. 1998. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob. Agents Chemother. 42:22402244.
111. Jabs, D. A.,, and P. D. Griffiths. 2002. Fomivirsen for the treatment of cytomegalovirus retinitis. Am. J. Ophthalmol. 133:552556.
112. Jacobson, M. A.,, J. Gallant,, L. H. Wang,, D. Coakley,, S. Weller,, D. Gary,, L. Squires,, M. L. Smiley,, M. R. Blum, and, J. Feinberg. 1994. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 38:15341540.
113. Jacobson, M. A.,, F. Kramer,, Y. Bassiakos,, T. Hooton,, B. Polsky,, H. Geheb,, J. J. O’Donnell,, J. D. Walker,, J. A. Korvick, and, C. van der Horst. 1994. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS Clinical Trials Group Protocol 151. J. Infect. Dis. 170:189193.
114. Jacobson, M. A.,, and J. Mills. 1988. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann. Intern. Med. 108:585594.
115. Jacobson, M. A.,, S. Wilson,, H. Stanley,, C. Holtzer,, J. Cherrington, and, S. Safrin. 1999. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. Clin. Infect. Dis. 28:528533.
116. Janssen, H. L.,, M. van Zonneveld,, H. Senturk,, S. Zeuzem,, U. S. Akarca,, Y. Cakaloglu,, C. Simon,, T. M. So,, G. Gerken,, R. A. de Man,, H. G. Niesters,, P. Zondervan,, B. Hansen, and, S. W. Schalm. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123129.
117. Kaiser, L.,, C. E. Crump, and, F. G. Hayden. 2000. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antivir. Res. 47:215220.
118. Karupiah, G.,, Q. W. Xie,, R. M. Buller,, C. Nathan,, C. Duarte, and, J. D. MacMicking. 1993. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 261:14451448.
119. Kati, W. M.,, A. S. Saldivar,, F. Mohamadi,, H. L. Sham,, W. G. Laver, and, W. E. Kohlbrenner. 1998. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains. Biochem. Biophys. Res. Commun. 244:408413.
120. Keam, S. J.,, T. M. Chapman, and, D. P. Figgitt. 2004. Brivudin (bromovinyl deoxyuridine). Drugs 64:20912097; discussion, 2098–2099.
121. Kempf, D. J.,, C. Klein,, H. J. Chen,, L. L. Klein,, C. Yeung,, J. T. Randolph,, Y. Y. Lau,, L. E. Chovan,, Z. Guan,, L. Hernandez,, T. M. Turner,, P. J. Dandliker, and, K. C. Marsh. 2007. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir. Chem. Chemother. 18:163167.
122. Kinghorn, G. R.,, E. B. Turner,, I. G. Barton,, C. W. Potter,, C. A. Burke, and, A. P. Fiddian. 1983. Efficacy of topical acyclovir cream in first and recurrent episodes of genital herpes. Antivir. Res. 3:291301.
123. Kirsch, L. S.,, J. F. Arevalo,, E. Chavez de la Paz,, D. Munguia,, E. de Clercq, and, W. R. Freeman. 1995. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 102:533542; discussion, 542–543.
124. Klumpp, K.,, V. Leveque,, S. Le Pogam,, H. Ma,, W. R. Jiang,, H. Kang,, C. Granycome,, M. Singer,, C. Laxton,, J. Q. Hang,, K. Sarma,, D. B. Smith,, D. Heindl,, C. J. Hobbs,, J. H. Merrett,, J. Symons,, N. Cammack,, J. A. Martin,, R. Devos, and, I. Najera. 2006. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281:37933799.
125. Knox, K. K.,, W. R. Drobyski, and, D. R. Carrigan. 1991. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 337:12921293.
126. Koff, W. C.,, J. L. Elm, Jr., and, S. B. Halstead. 1980. Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob. Agents Chemother. 18:125129.
127. Korba, B. E.,, A. B. Montero,, K. Farrar,, K. Gaye,, S. Mukerjee,, M. S. Ayers, and, J. F. Rossignol. 2007. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir. Res. 77:5663.
128. Krawitt, E. L.,, T. Ashikaga,, S. R. Gordon,, N. Ferrentino,, M. A. Ray, and, S. D. Lidofsky. 2005. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J. Hepatol. 43:243249.
129. Krosky, P. M.,, M. C. Baek, and, D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905914.
130. Krown, S. E. 1987. The role of interferon in the therapy of epidemic Kaposi’s sarcoma. Semin. Oncol. 14:2733.
131. Kuppermann, B. D.,, J. I. Quiceno,, M. Flores-Aguilar,, J. D. Connor,, E. V. Capparelli,, C. H. Sherwood, and, W. R. Freeman. 1993. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J. Infect. Dis. 168:15061509.
132. Lai, C.-L.,, R.-N. Chien,, N. W. Y. Leung,, T.-T. Chang,, R. Guan,, D.-I. Tai,, K.-Y. Ng,, P.-C. Wu,, J. C. Dent,, J. Barber,, S. L. Stephenson, and, D. F. Gray for the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:6168.
133. Lai, C. L.,, E. Gane,, Y. F. Liaw,, C. W. Hsu,, S. Thongsawat,, Y. Wang,, Y. Chen,, E. J. Heathcote,, J. Rasenack,, N. Bzowej,, N. V. Naoumov,, A. M. Di Bisceglie,, S. Zeuzem,, Y. M. Moon,, Z. Goodman,, G. Chao,, B. F. Constance, and, N. A. Brown. 2007. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357:25762588.
134. Lai, C. L.,, N. Leung,, E. K. Teo,, M. Tong,, F. Wong,, H. W. Hann,, S. Han,, T. Poynard,, M. Myers,, G. Chao,, D. Lloyd, and, N. A. Brown. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528536.
135. Lai, C. L.,, S. G. Lim,, N. A. Brown,, X. J. Zhou,, D. M. Lloyd,, Y. M. Lee,, M. F. Yuen,, G. C. Chao, and, M. W. Myers. 2004. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40:719726.
136. Lai, C. L.,, D. Shouval,, A. S. Lok,, T. T. Chang,, H. Cheinquer,, Z. Goodman,, D. DeHertogh,, R. Wilber,, R. C. Zink,, A. Cross,, R. Colonno, and, L. Fernandes. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354:10111020.
137. Lalezari, J.,, T. Schacker,, J. Feinberg,, J. Gathe,, S. Lee,, T. Cheung,, F. Kramer,, H. Kessler,, L. Corey,, W. L. Drew,, J. Boggs,, B. McGuire,, H. S. Jaffe, and, S. Safrin. 1997. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovirunresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 176:892898.
138. Lalezari, J. P.,, J. A. Aberg,, L. H. Wang,, M. B. Wire,, R. Miner,, W. Snowden,, C. L. Talarico,, S. Shaw,, M. A. Jacobson, and, W. L. Drew. 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:29692976.
139. Lalezari, J. P.,, W. L. Drew,, E. Glutzer,, C. James,, D. Miner,, J. Flaherty,, P. E. Fisher,, K. Cundy,, J. Hannigan,, J. C. Martin, et al. 1995. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:788796.
140. Lalezari, J. P.,, G. N. Holland,, F. Kramer,, G. F. McKinley,, C. A. Kemper,, D. V. Ives,, R. Nelson,, W. D. Hardy,, B. D. Kuppermann,, D. W. Northfelt,, M. Youle,, M. Johnson,, R. A. Lewis,, D. V. Weinberg,, G. L. Simon,, R. A. Wolitz,, A. E. Ruby,, R. J. Stagg, and, H. S. Jaffe. 1998. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:339344.
141. Lau, D. T.,, M. F. Khokhar,, E. Doo,, M. G. Ghany,, D. Herion,, Y. Park,, D. E. Kleiner,, P. Schmid,, L. D. Condreay,, J. Gauthier,, M. C. Kuhns,, T. J. Liang, and, J. H. Hoofnagle. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828834.
142. Lee, C.,, M. Loeb,, A. Phillips,, J. Nesbitt,, K. Smith, and, M. Fearon. 2000. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect. Control Hosp. Epidemiol. 21:700704.
143. Leeds, J. M.,, S. P. Henry,, L. Truong,, A. Zutshi,, A. A. Levin, and, D. Kornbrust. 1997. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab. Dispos. 25:921926.
144. Leone, P. A.,, S. Trottier, and, J. M. Miller. 2002. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin. Infect. Dis. 34:958962.
145. Li, K.,, E. Foy,, J. C. Ferreon,, M. Nakamura,, A. C. Ferreon,, M. Ikeda,, S. C. Ray,, M. Gale, Jr., and, S. M. Lemon. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 102:29922997.
146. Limaye, A. P.,, L. Corey,, D. M. Koelle,, C. L. Davis, and, M. Boeckh. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645649.
147. Reference deleted.
148. Lin, C.-C.,, D. Lourenco,, G. Xu, and, L.-T. Yeh. 2004. Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver. Antimicrob. Agents Chemother. 48:18721875.
149. Ljungman, P. 2001. Prophylaxis against herpesvirus infections in transplant recipients. Drugs 61:187196.
150. Manns, M. P.,, J. G. McHutchison,, S. C. Gordon,, V. K. Rustgi,, M. Shiffman,, R. Reindollar,, Z. D. Goodman,, K. Koury,, M. Ling, and, J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958965.
151. Marcelletti, J. F. 2002. Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs. Antivir. Res. 56:153166.
152. Marcellin, P.,, T. T. Chang,, S. G. Lim,, M. J. Tong,, W. Sievert,, M. L. Shiffman,, L. Jeffers,, Z. Goodman,, M. S. Wulfsohn,, S. Xiong,, J. Fry, and, C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808816.
153. Marfori, J. E.,, M. M. Exner,, G. I. Marousek,, S. Chou, and, W. L. Drew. 2007. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J. Clin. Virol. 38:120125.
154. Markham, A.,, and D. Faulds. 1994. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 48:455484.
155. Martin, D. F.,, B. D. Kuppermann,, R. A. Wolitz,, A. G. Palestine,, H. Li, and, C. A. Robinson for The Roche Ganciclovir Study Group. 1999. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N. Engl. J. Med. 340:10631070.
156. McMahon, M. A.,, B. L. Jilek,, T. P. Brennan,, L. Shen,, Y. Zhou,, M. Wind-Rotolo,, S. Xing,, S. Bhat,, B. Hale,, R. Hegarty,, C. R. Chong,, J. O. Liu,, R. F. Siliciano, and, C. L. Thio. 2007. The HBV drug entecavir—effects on HIV-1 replication and resistance. N. Engl. J. Med. 356:26142621.
157. Mercorelli, B.,, E. Sinigalia,, A. Loregian, and, G. Palú. 2008. Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev. Med. Virol. 18:177210.
158. Meurs, E.,, K. Chong,, J. Galabru,, N. S. Thomas,, I. M. Kerr,, B. R. Williams, and, A. G. Hovanessian. 1990. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62:379390.
159. Meylan, E.,, J. Curran,, K. Hofmann,, D. Moradpour,, M. Binder,, R. Bartenschlager, and, J. Tschopp. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:11671172.
160. Monto, A. S.,, J. L. McKimm-Breschkin,, C. Macken,, A. W. Hampson,, A. Hay,, A. Klimov,, M. Tashiro,, R. G. Webster,, M. Aymard,, F. G. Hayden, and, M. Zambon. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:23952402.
161. Monto, A. S.,, A. Webster, and, O. Keene. 1999. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother. 44(Suppl. B):2329.
162. Moore, M. L.,, M. H. Chi,, W. Zhou,, K. Goleniewska,, J. F. O’Neal,, J. N. Higginbotham, and, R. S. Peebles, Jr. 2007. Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J. Immunol. 178:26512654.
163. Moscona, A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:13631373.
164. Mulamba, G. B.,, A. Hu,, R. F. Azad,, K. P. Anderson, and, D. M. Coen. 1998. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42:971973.
165. Naoumov, N. V.,, A. R. Lopes,, P. Burra,, L. Caccamo,, R. M. Iemmolo,, R. A. de Man,, M. Bassendine,, J. G. O’Grady,, B. C. Portmann,, G. Anschuetz,, C. A. Barrett,, R. Williams, and, M. Atkins. 2001. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J. Hepatol. 34:888894.
166. Neyts, J.,, R. Snoeck,, J. Balzarini, and, E. De Clercq. 1991. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antivir. Res. 16:4152.
167. Noble, S.,, and K. L. Goa. 1999. Adefovir dipivoxil. Drugs 58:479487; discussion, 488–489.
168. Ong, A. K.,, and F. G. Hayden. 2007. John F. Enders lecture 2006: antivirals for influenza. J. Infect. Dis. 196:181190.
169. Ono, S. K.,, N. Kato,, Y. Shiratori,, J. Kato,, T. Goto,, R. F. Schinazi,, F. J. Carrilho, and, M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Investig. 107:449455.
170. Oxford, J. S.,, and A. Galbraith. 1980. Antiviral activity of amantadine: a review of laboratory and clinical data. Pharmacol. Ther. 11:181262.
171. Paeshuyse, J.,, A. Kaul,, E. De Clercq,, B. Rosenwirth,, J. M. Dumont,, P. Scalfaro,, R. Bartenschlager, and, J. Neyts. 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43:761770.
172. Painter, G. R.,, and K. Y. Hostetler. 2004. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 22:423427.
173. Patel, R.,, N. J. Bodsworth,, P. Woolley,, B. Peters,, G. Vejlsgaard,, S. Saari,, A. Gibb, and, J. Robinson. 1997. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin. Med. 73:105109.
174. Pavlovic, J.,, T. Zurcher,, O. Haller, and, P. Staeheli. 1990. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J. Virol. 64:33703375.
175. Perni, R. B.,, S. J. Almquist,, R. A. Byrn,, G. Chandorkar,, P. R. Chaturvedi,, L. F. Courtney,, C. J. Decker,, K. Dinehart,, C. A. Gates,, S. L. Harbeson,, A. Heiser,, G. Kalkeri,, E. Kolaczkowski,, K. Lin,, Y. P. Luong,, B. G. Rao,, W. P. Taylor,, J. A. Thomson,, R. D. Tung,, Y. Wei,, A. D. Kwong, and, C. Lin. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50:899909.
176. Perrillo, R. P.,, E. R. Schiff,, G. L. Davis,, H. C. Bodenheimer, Jr.,, K. Lindsay,, J. Payne,, J. L. Dienstag,, C. O’Brien,, C. Tamburro,, I. M. Jacobson, et al. 1990. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 323:295301.
177. Pescovitz, M. D.,, J. Rabkin,, R. M. Merion,, C. V. Paya,, J. Pirsch,, R. B. Freeman,, J. O’Grady,, C. Robinson,, Z. To,, K. Wren,, L. Banken,, W. Buhles, and, F. Brown. 2000. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44:28112815.
178. Peters, M. G.,, J. Andersen,, P. Lynch,, T. Liu,, B. Alston-Smith,, C. L. Brosgart,, J. M. Jacobson,, V. A. Johnson,, R. B. Pollard,, J. F. Rooney,, K. E. Sherman,, S. Swindells, and, B. Polsky. 2006. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44:11101116.
179. Pfeiffer, J. K.,, and K. Kirkegaard. 2005. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 79:23462355.
180. Polis, M. A.,, K. M. Spooner,, B. F. Baird,, J. F. Manischewitz,, H. S. Jaffe,, P. E. Fisher,, J. Falloon,, R. T. Davey, Jr.,, J. A. Kovacs,, R. E. Walker,, S. M. Whitcup,, R. B. Nussenblatt,, H. C. Lane, and, H. Masur. 1995. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother. 39:882886.
181. Prongay, A. J.,, Z. Guo,, N. Yao,, J. Pichardo,, T. Fischmann,, C. Strickland,, J. Myers, Jr.,, P. C. Weber,, B. M. Beyer,, R. Ingram,, Z. Hong,, W. W. Prosise,, L. Ramanathan,, S. S. Taremi,, T. Yarosh-Tomaine,, R. Zhang,, M. Senior,, R. S. Yang,, B. Malcolm,, A. Arasappan,, F. Bennett,, S. L. Bogen,, K. Chen,, E. Jao,, Y. T. Liu,, R. G. Lovey,, A. K. Saksena,, S. Venkatraman,, V. Girijavallabhan,, F. G. Njoroge, and, V. Madison. 2007. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2 (S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3 dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexan-2(S)-carboxamide (Sch 503034). II. Key steps in structure-based optimization. J. Med. Chem. 50:23102318.
182. Ptak, R. G.,, P. A. Gallay,, D. Jochmans,, A. P. Halestrap,, U. T. Ruegg,, L. A. Pallansch,, M. D. Bobardt,, M.-P. de Béthune,, J. Neyts,, E. De Clercq,, J.-M. Dumont,, P. Scalfaro,, K. Besseghir,, R. M. Wenger, and, B. Rosenwirth. 2008. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob. Agents Chemother. 52:13021317.
183. Raza, K.,, S. B. Ismailjee,, M. Crespo,, S. M. Studer,, S. Sanghavi,, D. L. Paterson,, E. J. Kwak,, C. R. Rinaldo, Jr.,, J. M. Pilewski,, K. R. McCurry, and, S. Husain. 2007. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J. Heart Lung Transplant. 26:862864.
184. Read, R. C.,, F. J. Vilar, and, T. L. Smith. 1998. AIDS-related herpes simplex virus encephalitis during maintenance foscarnet therapy. Clin. Infect. Dis. 26:513514.
185. Reddy, R.,, M. Rodriguez-Torres,, E. Gane,, R. Robson,, J. Lalezari,, G. T. Everson,, E. DeJesus,, J. G. McHutchinson,, H. E. Vargas,, A. Beard,, C. A. Rodriguez,, G. Z. Hill,, W. T. Symonds, and, M. M. Berry. 2007. Abstr. LB9. Abstr. 58th Annu. Meet. Am. Assoc. Study Liver Dis.
186. Reece, P. A. 2007. Neuraminidase inhibitor resistance in influenza viruses. J. Med. Virol. 79:15771586.
187. Reed, E. C.,, J. L. Wolford,, K. J. Kopecky,, K. E. Lilleby,, P. S. Dandliker,, J. L. Todaro,, G. B. McDonald, and, J. D. Meyers. 1990. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann. Intern. Med. 112:505510.
188. Reesink, H. W.,, S. Zeuzem,, C. J. Weegink,, N. Forestier,, A. van Vliet,, J. van de Wetering de Rooij,, L. McNair,, S. Purdy,, R. Kauffman,, J. Alam, and, P. L. Jansen. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebocontrolled, randomized study. Gastroenterology 131:9971002.
189. Reichman, R. C.,, D. Oakes,, W. Bonnez,, D. Brown,, H. R. Mattison,, A. Bailey-Farchione,, M. H. Stoler,, L. M. Demeter,, S. K. Tyring,, L. Miller, et al. 1990. Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J. Infect. Dis. 162:12701276.
190. Reusser, P.,, H. Einsele,, J. Lee,, L. Volin,, M. Rovira,, D. Engelhard,, J. Finke,, C. Cordonnier,, H. Link, and, P. Ljungman. 2002. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99:11591164.
191. Rooney, J. F.,, S. E. Straus,, M. L. Mannix,, C. R. Wohlenberg,, D. W. Alling,, J. A. Dumois, and, A. L. Notkins. 1993. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann. Intern. Med. 118:268272.
192. Sacks, S. L.,, R. A. Thisted,, T. M. Jones,, R. A. Barbarash,, D. J. Mikolich,, G. E. Ruoff,, J. L. Jorizzo,, L. B. Gunnill,, D. H. Katz,, M. H. Khalil,, P. R. Morrow,, G. J. Yakatan,, L. E. Pope, and, J. E. Berg. 2001. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 45:222230.
193. Safrin, S.,,